PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
30-Apr-2025  Equity (NAV) increases by almost EUR 27 million to EUR 277.9 million, corresponding to EUR 64.90 per share. EBIT increases by EUR 2.75 million to EUR 33.0 million. The equity ratio rises to 95.5%. MPH Health Care AG
30-Apr-2025 Drägerwerk AG & Co. KGaA: Dräger with strong demand in the first quarter of 2025 Drägerwerk AG & Co. KGaA
30-Apr-2025 Strong start in an environment marked by macroeconomic uncertainties Straumann Holding AG
29-Apr-2025 Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis ABIVAX
29-Apr-2025 aap Implantate AG: Postponement of the publication of the annual financial statements and consolidated financial statements for the financial year 2024 aap Implantate AG
29-Apr-2025 Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD Takeda
29-Apr-2025 Mainz Biomed Enters into Technology Partnership with EDX Medical Group Mainz BioMed N.V.
29-Apr-2025 Evotec SE to announce results for the first quarter 2025 on 6 May 2025 Evotec SE
29-Apr-2025 M1 Kliniken AG publishes preliminary figures for the 2024 financial year: Strong EBIT growth (+70%) and significant increase in earnings per share (+57%) M1 Kliniken AG
29-Apr-2025 AEVIS VICTORIA SA (AEVS.SW) – MRH Switzerland's positive momentum continues in the first quarter of 2025, driven by the operational excellence of its flagship establishments AEVIS VICTORIA SA
28-Apr-2025 Secarna Pharmaceuticals adds leading expert to Scientific Advisory Board with appointment of Prof. Dr. Vignali Secarna Pharmaceuticals GmbH & Co. KG
28-Apr-2025 Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval Mainz BioMed N.V.
28-Apr-2025 BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter on May 7, 2025 BioVersys AG
25-Apr-2025 Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025 Pentixapharm Holding AG
25-Apr-2025 Exclusive contract for ViroCAP® My Plasma with Landsberg First Class Aesthetic opens up Viromed's entry into the European cosmetics market Viromed Medical AG
25-Apr-2025 Xlife Sciences AG publishes 2024 Annual Report: Strategic Expansion, Technological Milestones, and International Capital Market Presence Xlife Sciences AG
24-Apr-2025 2024 FULL YEAR RESULTS Affluent Medical reached major new milestones in executing its clinical roadmap Affluent Medical SA
24-Apr-2025 Pentixapharm Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Eckert & Ziegler SE Pentixapharm Holding AG
24-Apr-2025 Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Pentixapharm Eckert & Ziegler SE
24-Apr-2025 Evotec announces significant progress in strategic protein degradation collaboration with Bristol Myers Squibb Evotec SE